NVAX Jumps 14.3% as EPS Estimate Revised to 97.3% Growth
Novavax (NVAX) led today's EPS-revision screen with a 14.3% gain to $12.82 after its next-year EPS growth estimate was revised from 77.3% to 97.3%. AGI Inc (AGBK) rose 13.4% to $7.38 with a 44.5% next-year EPS growth estimate, Vera Bradley (VRA) climbed 12.4% to $5.78 after a 63.6-point revision to 150.0%, Snap (SNAP) added 11.7% to $6.49 following a 12-point revision to 411.7%, and Alignment Healthcare (ALHC) gained 9.9% to $8.30 despite a Medicare star-rating downgrade.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| NVAX | Healthcare | 2026-10-07 | +20.0pp | +14.3% |
| AGBK | Financial | 2026-10-08 | N/A | +13.4% |
| VRA | Consumer Cyclical | 2026-10-09 | +63.6pp | +12.4% |
| SNAP | Communication Services | 2026-10-07 | +12.0pp | +11.7% |
| ALHC | Healthcare | 2026-10-09 | +6.6pp | +9.9% |
Why did NVAX stock jump in October 2026?
NVAX jumped 14.3% to $12.82 after analysts raised its next-year EPS growth estimate from 77.3% to 97.3% on October 7, 2026.
The 20-point revision pushed Novavax toward near-doubling earnings growth, driving buyers into the beaten-down vaccine maker despite no company-specific news in the window. The lack of any earnings-related headline confirms the move was driven purely by the underlying estimate revision rather than a one-day event, and the sustained follow-through over the following week suggests broader healthcare interest in names with improving forward profitability.
NVAX EPS revision history → · Screener snapshot from 2026-10-07 →
FAQ: NVAX
Why did NVAX stock jump on October 7, 2026?
NVAX jumped 14.3% to $12.82 after its next-year EPS growth estimate was revised from 77.3% to 97.3% on October 7, 2026.
What is NVAX's EPS growth estimate?
Novavax's next-year EPS growth estimate stands at 97.3%, up from 77.3% before the October 7 revision.
Is NVAX a buy after the rally?
The move was driven entirely by an EPS estimate revision rather than company news, so investors should weigh the sustainability of that growth estimate before chasing the 14.3% gain.
Why did AGBK stock jump in October 2026?
AGBK jumped 13.4% to $7.38 after being detected by our EPS screener on October 8, 2026 with a current next-year EPS growth estimate of 44.5%.
AGI Inc, a financial-sector name, drew buyers as the estimate confirmed strong forward profitability without any accompanying earnings-relevant news in the window. The gain fits the broader pattern of small financials rallying on improving growth expectations, and the clean price follow-through indicates accumulation rather than a headline-driven spike.
AGBK EPS revision history → · Screener snapshot from 2026-10-08 →
FAQ: AGBK
Why did AGBK stock jump on October 8, 2026?
AGBK jumped 13.4% to $7.38 after being flagged by our EPS revision screener with a next-year EPS growth estimate of 44.5%.
What is AGBK's EPS growth estimate?
AGI Inc's current next-year EPS growth estimate is 44.5%.
What caused AGBK's surge?
A strong 44.5% forward EPS growth estimate caught screener attention on October 8, 2026, with no accompanying news in the window.
Why did VRA stock jump in October 2026?
VRA jumped 12.4% to $5.78 after analysts revised Vera Bradley's next-year EPS growth estimate from 86.4% to 150.0% on October 9, 2026.
The 63.6-point upward revision was the largest in today's screen, and with no earnings-related news in the window, the move reflects pure estimate-driven buying in the consumer cyclical name. The magnitude of the revision to 150% growth signals a sharp expected swing in profitability at Vera Bradley, and the market responded by pushing the stock up more than 12% in the days following detection.
VRA EPS revision history → · Screener snapshot from 2026-10-09 →
FAQ: VRA
Why did VRA stock jump on October 9, 2026?
VRA jumped 12.4% to $5.78 after its next-year EPS growth estimate was raised from 86.4% to 150.0% on October 9, 2026.
What is VRA's EPS growth estimate?
Vera Bradley's next-year EPS growth estimate is now 150.0%, up sharply from 86.4%.
What caused VRA's surge?
The largest revision in today's screen — a 63.6-point increase to 150.0% next-year EPS growth — drove the 12.4% rally with no accompanying news.
Why did SNAP stock jump in October 2026?
SNAP jumped 11.7% to $6.49 after its next-year EPS growth estimate was revised from 399.7% to 411.7% on October 7, 2026.
The revision was reinforced by activist news: Blue Duck Capital's October 6 open letter urged the Snap board to raise external capital for Specs, arguing a sum-of-the-parts re-rating could more than double the share price to $12-$14 and that Specs alone is worth $5 billion. Snap also announced the date of its Q3 2026 results conference call on October 8, adding a near-term catalyst, and the combination of the estimate revision plus activist pressure drove the stock's 11.7% gain.
SNAP EPS revision history → · Screener snapshot from 2026-10-07 →
FAQ: SNAP
Why did SNAP stock jump on October 7, 2026?
SNAP jumped 11.7% to $6.49 after its next-year EPS growth estimate was revised from 399.7% to 411.7%, reinforced by Blue Duck Capital's October 6 activist letter urging a Specs spinoff or external capital raise.
What is SNAP's EPS growth estimate?
Snap's next-year EPS growth estimate is 411.7%, up from 399.7% before the October 7 revision.
Is SNAP a buy after the Blue Duck Capital letter?
Blue Duck argues a sum-of-the-parts re-rating could take SNAP to $12-$14, but the stock's 411.7% EPS growth estimate reflects a very low earnings base, so position sizing should account for that volatility.
Why did ALHC stock jump in October 2026?
ALHC jumped 9.9% to $8.30 after its next-year EPS growth estimate was revised from 129.4% to 136.1% on October 9, 2026.
The rally came despite a same-day 20% premarket plunge after Medicare's 2027 Star Ratings cut the California HMO contract serving about 75% of members to 3.5 stars from 4.0, putting 2028 quality bonus payments at risk. Alignment said it expects no revenue impact in 2026 or 2027, plans appeals and a lawsuit, and sees provider risk-sharing offsetting part of the hit; JPMorgan and KeyBanc cut targets to $10 and $12. The stock's recovery from that selloff to a 9.9% gain since detection shows buyers focusing on the forward EPS revision rather than the star-rating headline.
ALHC EPS revision history → · Screener snapshot from 2026-10-09 →
FAQ: ALHC
Why did ALHC stock jump on October 9, 2026?
ALHC jumped 9.9% to $8.30 after its next-year EPS growth estimate was revised from 129.4% to 136.1%, even as the stock initially fell 20% on a Medicare star-rating downgrade.
What is ALHC's EPS growth estimate?
Alignment Healthcare's next-year EPS growth estimate is 136.1%, up from 129.4%.
What happened with ALHC's Medicare star ratings?
Medicare's 2027 Star Ratings downgraded Alignment's California HMO contract to 3.5 stars from 4.0 on October 9, 2026, putting 2028 quality bonus payments at risk; the company expects no 2026 or 2027 revenue impact and plans to appeal.
Today's screen shows investors rewarding pure EPS estimate revisions across healthcare, financials, consumer cyclicals, and communication services, even when headlines are absent or negative. The breadth of the moves — five names, three sectors, and gains of 9.9% to 14.3% — suggests the market is actively hunting for improving forward profitability rather than waiting for confirmed results.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →